TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12848626
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (15-25 mg)
Study: 10589962
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (MMF, CsA, and prednisone)
Study: 10589962
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of CsA (group B)
Study: 10589962
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of triple therapy (group A)
Study: 10589962
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of prednisone (group C)
Study: 1872925
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil dietary supplementation (10 g/day)
Study: 6343861
Drug: Acyclovir (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (1500 mg/m²/day for one week)
Study: 3709648
Drug: MDL 72.222,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72.222, 20 mg (slow i.v. injection)
Study: 18373843
Drug: GEM+X (gemcitabine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM+X (gemcitabine-based combination chemotherapy)
Study: 16931265
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anterior capsule polishing)
Study: 9091027
Drug: Doxazosin (1-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-16 mg, mean final dose 6.1 mg)
Study: 9091027
Drug: Nitrendipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10-20 mg, mean final dose 15.6 mg)
Study: 8365297
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (2 g IV over 20 min followed by 2 g/h over 4 h)
Study: 8365297
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate bolus (2 g over 20 min followed by placebo infusion)
Study: 8365297
Drug: Placebo (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (loading dose and infusion)
Study: 27301489
Drug: Organisational change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organisational change intervention including smoke-free policy development, staff training, educational resources, and free nicotine replacement therapy.
Study: 25187104
Drug: Glucose with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose with 2.4 g · kg(‐1) · day(‐1) amino acids
Study: 18246696
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg 4 times daily for adults; 20 to 40 mg/kg daily in 4 divided doses for children
Study: 18246696
Drug: Placebo (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (an emollient cream)
Study: 16540709
Drug: Intermittent hypoxia
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent hypoxia training (IHT) in hypoxia (FiO2 = 14.5%); 6 weeks duration; included two weekly high-intensity training sessions.
Study: 16540709
Drug: Normoxia training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoxia training (Nor group; FiO2 = 20.9%); 6 weeks duration; included two weekly high-intensity training sessions.
Study: 9412256
Drug: 0.4 g.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g.kg-1 HBOC-201
Study: 9412256
Drug: 3 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml.kg-1 6% HES 70,000/0.5
Study: 8241226
Drug: Cyclosporine target
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine target trough level reduced from 400-600 micrograms/L to 200-400 micrograms/L (Group A)
Study: 8241226
Drug: Cyclosporine target
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine target trough level maintained at 400-600 micrograms/L (Group B)
Study: 22537207
Drug: Once-daily (q.d.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (q.d.) pramipexole
Study: 22537207
Drug: Three-times-daily (t.i.d.)
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily (t.i.d.) pramipexole
Study: 19190632
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg m(‐2), d1, d8, 100‐min infusion) and Oxaliplatin (100 mg m(‐2), d1)
Study: 19190632
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and Oxaliplatin combination
Study: 12548062
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg)
Study: 12194635
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg)
Study: 12374899
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg)
Study: 9366100
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg (PIR)
Study: 9366100
Drug: Altizide 15
Normalized name: althiazide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altizide 15 mg - Spironolactone 25 mg (ALT-SP)
Study: 9366100
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (PIR, HCT, ALT-SP)
Study: 3910541
Drug: Rosoxacin 150
Normalized name: rosoxacin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosoxacin 150 mg twice daily for 10 days
Study: 3910541
Drug: Triple tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple tetracycline (Deteclo) 300 mg twice daily for 10 days
Study: 31880078
Drug: Home-based pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based pulmonary rehabilitation (8 weeks, one home visit and seven once-weekly telephone calls)
Study: 31880078
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (weekly social telephone calls)
Study: 22801416
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin/10 mg ezetimibe
Study: 15899726
Drug: Metabolife Ephedra
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolife Ephedra Free (half the normal recommended dose)
Study: 12789955
Drug: Oral‐B Stages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Stages toothbrushes
Study: 9583761
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 mg) plus benserazide (25 mg) taken three times per day for 28 days
Study: 9450173
Drug: Tablet (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (treatment A)
Study: 9450173
Drug: Capsule (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule (treatment B, Gramidil)
Study: 21771770
Drug: IVIG 0.5‐1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 0.5‐1.0 g/kg
Study: 21771770
Drug: IVIG 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 0.5 g/kg
Study: 21771770
Drug: IVIG 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1.0 g/kg
Study: 19416445
Drug: Baseline (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (before any dental treatment)
Study: 8498314
Drug: Amlodipine 1.25
Normalized name: levamlodipine 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 1.25 mg daily
Study: 8498314
Drug: Amlodipine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5.0 mg daily
Study: 8498314
Drug: Amlodipine 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10.0 mg daily
Study: 8498314
Drug: Amlodipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (all doses > 1.25 mg)
Study: 3549810
Drug: 3% topical
Normalized name: Triaz 3% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% topical minoxidil applied twice daily for 64 weeks
Study: 3549810
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks, then 3% topical minoxidil for 52 weeks
Study: 3549810
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of 3% topical minoxidil for a second year
Study: 26559015
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg.kg(‐1))
Study: 24566571
Drug: Capilen® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capilen® cream
Study: 20408017
Drug: Liquid carbon
Normalized name: calcium carbonate Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid carbon dioxide cooling shirt (CC)
Study: 18758393
Drug: Antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drugs (lamivudine, stavudine, zidovudine, nevirapine, nelfinavir, ritonavir, lopinavir) measured in breast milk using a novel extraction method and high-performance liquid chromatography-tandem mass spectrometry.
Study: 10500060
Drug: Norfloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (800 mg/day)
Study: 10500060
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (1500 mg/day)
Study: 1986897
Drug: Nitroprusside administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside administered using Abbott infusion pump
Study: 1986897
Drug: Nitroprusside administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside administered using IMED infusion pump
Study: 1986897
Drug: Nitroprusside administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside administered using 3M/AVI infusion pump
Study: 1986897
Drug: Nitroprusside administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside administered using IVAC infusion pump
Study: 1986897
Drug: Nitroprusside administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside administered using Kendall McGaw infusion pump
Study: 6340183
Drug: Carprofen, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen, 300 mg/day
Study: 6340183
Drug: Indomethacin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 75 mg/day
Study: 27484710
Drug: Multipurpose solutions
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multipurpose solutions (MPS)
Study: 25103686
Drug: e‐Exercise (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐Exercise (12-week intervention with maximum five face‐to‐face physical therapy contacts and a web‐based program)
Study: 15014270
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (physical therapy)
Study: 20008708
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (1 mg)
Study: 16828501
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (4 mg)
Study: 20008708
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (control group)
Study: 15105032
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g beta‐hydroxy‐beta‐methylbutyrate, 5 g arginine, and 1.5 g lysine daily
Study: 9876807
Drug: Intraperitoneal fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal fluconazole 200 mg
Study: 7866603
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg twice daily
Study: 7866603
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of captopril and ISDN
Study: 2510288
Drug: indomethacin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin, 75 mg and 50 mg
Study: 2510288
Drug: baseline, no
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline, no treatment
Study: 31381364
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - loading dose followed by continuous infusion for 48 hours
Study: 26129900
Drug: Dalitong granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalitong granule (DG) 6 g 3 times daily
Study: 26129900
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at points Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6), Taichong (LR3), Gongsun (SP4) twice daily
Study: 26129900
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of DG and EA
Study: 26129900
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 5 mg mosapride 3 times, 20 mg pantoprazole, and 25 mg amitriptyline twice daily
Study: 22097156
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg/kg per day or 3 mg/kg per day)
Study: 17895911
Drug: Flexible administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible administration of micronutrient Sprinkles over 4 months
Study: 17895911
Drug: Flexible administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible administration of micronutrient Sprinkles over 3 months
Study: 17895911
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of micronutrient Sprinkles over 2 months
Study: 12975660
Drug: TAC (docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy (75/50/500 mg/m2 6x q3wk)
Study: 12975660
Drug: FAC (5‐fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) chemotherapy (500/50/500 mg/m2 6x q3wk)
Study: 11079643
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg daily for four weeks)
Study: 8947886
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b (r-IFN-alpha 2b) at doses of 5, 2.5, or 1.25 million units (MU) daily for a minimum of 14 days prior to transplantation and continuing for 42 days post-transplantation.
Study: 8947886
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b (r-IFN-alpha 2b) treatment.
Study: 30488222
Drug: Three-drug control
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug control
Study: 25279818
Drug: Noribogaine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine 60 mg
Study: 27870477
Drug: Noribogaine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine 120 mg
Study: 27870477
Drug: Noribogaine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noribogaine 180 mg
Study: 24993856
Drug: Dual-phase calcium
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-phase calcium silicate/phosphate gel combined with calcium silicate/phosphate toothpaste (TG+TP)
Study: 12161765
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (Viagra) 25, 50 or 100 mg
Study: 9883302
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray 0.03% (42 mcg per nostril) administered three times daily plus terfenadine 60 mg administered twice daily
Study: 9883302
Drug: Vehicle nasal
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle nasal spray plus terfenadine 60 mg administered twice daily
Study: 9883302
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray plus terfenadine
Study: 9883302
Drug: Vehicle nasal
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle nasal spray plus terfenadine
Study: 7543494
Drug: rhIGF‐I administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I administration
Study: 2087049
Drug: RBA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBA with adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase, after‐mixing concentration 1:500,000)
Study: 2087049
Drug: RBA without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RBA without adrenaline (5 ml of a lidocaine‐bupivacaine mixture with hyaluronidase)
Study: 650879
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/ml and Diazepam 0.1 mg/ml administered by intravenous drip at a rate of 0.1 ml/kg/min for the first 5 min and 0.017 ml/kg/min for the next 15 min.
Study: 650879
Drug: Droperidol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.125 mg/kg given intravenously before administration of ketamine-diazepam solution.
Study: 31810829
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (mobile health-based program with weekly automated assessment and behavior change calls, structured email feedback to caregivers, and fax alerts to clinicians)
Study: 27858951
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy fall reduction home visit program (IG)
Study: 21325226
Drug: Probiotic culture
Normalized name: Lactobacillus Reuteri/Lactobacillus rhamnosus/Probiotic Cultures 134 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic culture (FloraMax, IVS‐Wynco LLC) administered via oral gavage 1 hour post SH challenge.
Study: 14970962
Drug: regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: regular therapy
Study: 14970962
Drug: control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (no therapy)
Study: 9256515
Drug: Direct treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct treatment
Study: 30582880
Drug: Chitosan brush
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan brush treatment
Study: 30582880
Drug: Titanium curettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium curettes treatment
Study: 24621064
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) supplementation (500 mg/day)
Study: 22385121
Drug: 5% permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% permethrin cream (twice application with a 1-week interval)
Study: 22385121
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (single dose)
Study: 11837056
Drug: Back school
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back school with peer support (treatment group, n = 47)
Study: 10023644
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin infusion, 100 mL/d for 7 days
Study: 520164
Drug: Systemic forms
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic forms of administration (i.v. and i.m.)
Study: 18300848
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg/day
Study: 30973207
Drug: Nifedipine-GITS 30-60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-GITS 30-60 mg/day
Study: 30973207
Drug: Amlodipine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (after missing a dose)
Study: 29121269
Drug: FSH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH dose of 100 IU/day
Study: 29121269
Drug: FSH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH dose of 150 IU/day
Study: 23374559
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (daily for 6 months)
Study: 19383582
Drug: Pentoxifylline (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (800 mg/day orally) for 5 days before surgery
Study: 29888582
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (electroacupuncture, acupoint-injection, fire-needle)
Study: 23422097
Drug: Combined subfascial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined subfascial endoscopic perforator surgery (SEPS) and endovenous laser treatment (EVLT)
Study: 20440528
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of bovine type II collagen (bCII)
Study: 20440528
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of bovine type II collagen (bCII)
Study: 20440528
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg of bovine type II collagen (bCII)
Study: 17009230
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with MTX plus etanercept
Study: 10921554
Drug: Oxidized‐raffinose cross‐linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidized‐raffinose cross‐linked human hemoglobin (Hemolink) at doses of 0.025-0.6 g/kg
Study: 8612381
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) for 7 days